申请人:Incyte Corporation
公开号:US20190292188A1
公开(公告)日:2019-09-26
This application relates to compounds of Formula (I):
or pharmaceutically acceptable salts or stereoisomers thereof, which modulate the activity of adenosine receptors, such as subtypes A2A and A2B receptors, and are useful in the treatment of diseases related to the activity of adenosine receptors including, for example, cancer, inflammatory diseases, cardiovascular diseases, and neurodegenerative diseases.